Loomis, Sayles & Company
EGRX

Loomis, Sayles & Company’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Loomis, Sayles & Company’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-27
Closed -$1K – 1145
2016
Q1 		$1K Buy
+27
New +$1.71K ﹤0.01% 1029

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Loomis, Sayles & Company's EGRX Position: Q2 2016 in Review

Loomis, Sayles & Company sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2016, closing a stake of 27 shares — an estimated $1K sold.

Loomis, Sayles & Company first reported a position in EGRX in Q1 2016 and held it in 1 quarter. The position peaked at $1K in Q1 2016. 116 funds tracked by Wall St. Rank hold EGRX as of Q2 2016.

  • Loomis, Sayles & Company reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • Loomis, Sayles & Company sold 27 Eagle Pharmaceuticals, Inc. shares in Q2 2016, an estimated $1K.
  • Loomis, Sayles & Company first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2016 and held it in 1 quarter.
  • Loomis, Sayles & Company's Eagle Pharmaceuticals, Inc. position peaked at $1K in Q1 2016.
  • 116 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2016.

Based on Loomis, Sayles & Company's 13F filing for Q2 2016, filed 12 Aug 2016.